Yonatan Malca - 01 Jan 2026 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Reporting relationship: Director
Issuer ticker: ENTX
Reported as of: 01 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jan 2026, 16:23:29 UTC
Prior SEC filing: 17 Jan 2025
Next SEC filing: 25 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact

Key filing fact

Yonatan Malca filed Form 4 for Entera Bio Ltd. (ENTX) on 02 Jan 2026.

Key facts

This page summarizes Yonatan Malca's Form 4 filing for Entera Bio Ltd. (ENTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jan 2026, 16:23.

Change

Previous filing in this sequence was filed on 17 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001904759 Primary reporting owner

Malca Yonatan

Relationship: Director
Address: KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM, ISRAEL
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Signature date: 02 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTX transaction

Ordinary Shares, par value NIS 0.0000769 per share

Award

Transaction value: $0
Shares: +30,157
Change %: +64%
Price: $0.000000
Shares after: 77,416
Date: 01 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +33,505
Change %
Price: $0.000000
Shares after: 33,505
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Ordinary Shares, par value NIS 0.0000769 per share
Underlying amount: 33,505
Exercise price: $1.94
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.

Footnote F2

These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.